Welcome to our dedicated page for Evolv Technologies Hldngs SEC filings (Ticker: EVLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.
Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.
Evolv Technologies Holdings, Inc. amends its registration statement to convert the filing back to a Form S-3 and to continue the resale registration that covers 158,574,790 shares of Class A common stock and 5,700,000 private placement warrants, plus up to 14,325,000 shares issuable upon exercise of outstanding public and private warrants. The resale is by selling securityholders from time to time; the company will not receive proceeds from those resale transactions. The company would receive proceeds only if warrants are exercised for cash — the filing states aggregate cash proceeds of approximately $131.8 million if all outstanding warrants are exercised. The prospectus also discloses shares outstanding of 179,350,739 as of March 3, 2026 and market quotes of $6.05 per share and $0.116 per warrant as of March 31, 2026.
Evolv Technologies Holdings Inc: The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock, representing 0% of the class as of 03/13/2026.
The filing includes a disclosure that Vanguard completed an internal realignment on 01/12/2026, after which certain subsidiaries report ownership separately in reliance on SEC Release No. 34-39538. The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Evolv Technologies Holdings, Inc. describes itself as an AI-powered security technology company providing Security-as-a-Service weapons screening solutions for high-traffic venues such as schools, hospitals, sports and entertainment sites, industrial workplaces and houses of worship. Its Evolv Express and Evolv eXpedite platforms combine proprietary sensors, AI software, cloud connectivity and analytics under multi-year subscription or purchase-plus-subscription models.
The company reports continued losses, with net losses of $33.1 million in 2025 and $54.0 million in 2024, and an accumulated deficit of $387.8 million. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was about $999.0 million, and as of March 3, 2026, there were 179,350,739 Class A shares outstanding.
Evolv highlights recurring revenue metrics such as ARR and remaining performance obligations, a large addressable market of roughly 400,000 sites and 700,000 screening thresholds, and a strategy centered on metropolitan “lighthouse” customers, reseller expansion, new products and international growth. The filing also discloses material weaknesses in internal control over financial reporting that led to prior restatements, notes that remediation is ongoing, and warns of risks from supply chain dependence, competition, government regulation, and the possibility that its AI-based systems may fail or be perceived to fail to detect threats.
Evolv Technologies Holdings, Inc. describes itself as an AI-powered security technology company providing Security-as-a-Service weapons screening solutions for high-traffic venues such as schools, hospitals, sports and entertainment sites, industrial workplaces and houses of worship. Its Evolv Express and Evolv eXpedite platforms combine proprietary sensors, AI software, cloud connectivity and analytics under multi-year subscription or purchase-plus-subscription models.
The company reports continued losses, with net losses of $33.1 million in 2025 and $54.0 million in 2024, and an accumulated deficit of $387.8 million. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was about $999.0 million, and as of March 3, 2026, there were 179,350,739 Class A shares outstanding.
Evolv highlights recurring revenue metrics such as ARR and remaining performance obligations, a large addressable market of roughly 400,000 sites and 700,000 screening thresholds, and a strategy centered on metropolitan “lighthouse” customers, reseller expansion, new products and international growth. The filing also discloses material weaknesses in internal control over financial reporting that led to prior restatements, notes that remediation is ongoing, and warns of risks from supply chain dependence, competition, government regulation, and the possibility that its AI-based systems may fail or be perceived to fail to detect threats.
Evolv Technologies Holdings, Inc. reported strong fourth quarter and full-year 2025 results and raised its outlook for 2026. Q4 2025 revenue reached $38.5 million, up 32% year over year, with ending ARR of $120.5 million, up 21%. The company generated Q4 net income of $10.9 million and Adjusted EBITDA of $1.8 million.
For 2025, revenue grew to $145.9 million, a 40% increase from 2024, while net loss narrowed to $33.1 million and Adjusted EBITDA improved to $11.1 million. Operating activities provided $18.7 million of cash, and cash, cash equivalents and marketable securities totaled $69.0 million at year-end.
For 2026, the company expects total revenue of $172–$178 million and ending ARR of $145–$150 million, with positive full-year Adjusted EBITDA and margins in the high single digits, driven by a higher mix of recurring subscription revenue.
Evolv Technologies Holdings, Inc. reported strong fourth quarter and full-year 2025 results and raised its outlook for 2026. Q4 2025 revenue reached $38.5 million, up 32% year over year, with ending ARR of $120.5 million, up 21%. The company generated Q4 net income of $10.9 million and Adjusted EBITDA of $1.8 million.
For 2025, revenue grew to $145.9 million, a 40% increase from 2024, while net loss narrowed to $33.1 million and Adjusted EBITDA improved to $11.1 million. Operating activities provided $18.7 million of cash, and cash, cash equivalents and marketable securities totaled $69.0 million at year-end.
For 2026, the company expects total revenue of $172–$178 million and ending ARR of $145–$150 million, with positive full-year Adjusted EBITDA and margins in the high single digits, driven by a higher mix of recurring subscription revenue.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported an open-market sale of 91,771 shares of Class A common stock at a weighted average price of $5.10 per share. The sale was made under a Rule 10b5-1 trading plan entered into on June 12, 2025.
The footnotes state that individual trades occurred between $5.04 and $5.17. After this sale, Ellenbogen directly owned 2,083,961 shares, and separately had 151,135 shares held indirectly through the Family Horizon Trust as a reported holding.
EVLV filed a Form 144 notifying a proposed sale of Class A Common stock. The notice lists 161,490 shares tied to a stock option exercise (cash) dated 03/06/2026 and 91,771 shares from restricted stock vesting dated 03/01/2026. The filing also reports past sales by Michael P. Ellenbogen: 80,745 shares on each of 12/15/2025, 01/16/2026, and 02/17/2026.
Kedzierski John reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings President & CEO John Kedzierski received a grant of 373,831 Restricted Stock Units, each representing one share of Class A common stock at no cash cost. The RSUs vest in three equal annual installments beginning on March 2, 2027, and have no expiration date.
Marshall Robert E reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. reported that Chief Revenue Officer Robert E. Marshall received a grant of 186,915 Restricted Stock Units on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests in three equal annual installments starting on March 2, 2027.
Kutsor George C reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. reported that Chief Financial Officer George C. Kutsor received an equity award of 186,915 Restricted Stock Units (RSUs) on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.
The RSUs were granted at no cash cost and will vest in three equal annual installments starting on March 2, 2027, tying the CFO’s compensation to the company’s long-term performance and continued service.
Evolv Technologies Holdings director Michael Ellenbogen reported both RSU vesting and a small share sale. He sold 82,913 shares of Class A common stock in an open-market transaction at a weighted average price of $5.19 per share, with individual trades ranging from $5.19 to $5.29, solely to cover withholding taxes owed on vesting RSUs.
On the prior day, he exercised and converted 66,787, 57,392 and 50,505 Restricted Stock Units into the same number of Class A shares at no cost, reflecting scheduled vesting of RSU awards. Each RSU represents one share and has no expiration, vesting in three equal annual installments beginning on March 1 of 2024, 2025 and 2026, respectively.
After these transactions, Ellenbogen directly owns 2,175,732 shares of Evolv Class A common stock and also reports indirect ownership of 151,135 shares held by the Family Horizon Trust.